You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Early Warning system for detecting pre-eclampsia

    SBC: CONVERGENT ENGINEERING, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Enabling high dose regional chemotherapy while minimizing systemic toxicity

    SBC: VASCULAR VISION PHARMACEUTICAL CO            Topic: NCI

    DESCRIPTION (provided by applicant): Enabling high dose regional chemotherapy with minimal systemic toxicity Abstract: The primary objective of this proposed study is to develop a filtration system that maximizes the removal (gt90%) of chemotherapeutic agents, such as doxorubicin, from blood while minimizing adverse effects of filtration on blood chemistry and hematological parameters. Vascular V ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Enhanced bioscavenger for medical countermeasures against organophosphorus agents

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: NIEHS

    DESCRIPTION (provided by applicant): Counteracting the threat of intoxication by organophosphorus nerve agents (OP's) is an important mission for homeland security as well as for treating workers exposed to pesticides. OP's act on acetylcholinesterase to prevent synaptic inactivation, thereby leading to immobilization and death on sustained application. Currently, the most promising stra ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Epitaxial GaN on flexible metal tapes for low-cost transistor devices

    SBC: IBEAM MATERIALS, INC.            Topic: 1

    GaN-based devices are the basis of a variety of modern electronics applications, especially in optoelectronics and high-frequency / high-power electronics. These devices are based on epitaxial films grown on single-crystal wafers. The single-crystal wafer substrates are limiting because of their size, expense, mechanical properties and availability. If one could make GaN-based devices over large a ...

    STTR Phase I 2013 Department of EnergyARPA-E
  7. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent

    SBC: PHOTOLITEC LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Photolitec's patented technology is focused on developing improved agents for tumor- imaging, image-guided surgery and/or photodynamic therapy (PDT). The proposed STTR proposal includes fluorescence-image guided PDT, aSee and Treat approach. The fluorescence imaging compound with long wavelength absorption near 800 nm should be extremely useful for image ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency

    SBC: LEXEO Therapeutics LLC            Topic: 400

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene therapy strategy as a preventative therapy to protect individuals with aldehyde dehydrogenaseALDHdeficiency from the high risk for esophageal cancerAs the next step in the development paththe goal of this ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Gene Therapy to Protect the Lung from Oxidant Stress

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractThe focus of this proposal is the development of therapy to protect the lung with an extracellular anti oxidant defense to treat chronic obstructive pulmonary diseaseCOPDa chronic disorder in which inhaled oxidants from tobacco smokepollution and generated within the lung by activated inflammatory cells perpetuate injury to the lung epithelium and endotheliumThe LEXEO strategy is to use in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government